Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis

[1]  P. Fitzgerald,et al.  Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. , 2008, JAMA.

[2]  F. Eberli,et al.  Drug-eluting versus bare-metal stents in large coronary arteries. , 2010, The New England journal of medicine.

[3]  E. Peterson,et al.  Acceptance, panic, and partial recovery the pattern of usage of drug-eluting stents after introduction in the U.S. (a report from the American College of Cardiology/National Cardiovascular Data Registry). , 2010, JACC. Cardiovascular interventions.

[4]  Simon Wandel,et al.  Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.

[5]  R. Virmani,et al.  Endothelial cell recovery, acute thrombogenicity, and monocyte adhesion and activation on fluorinated copolymer and phosphorylcholine polymer stent coatings. , 2010, Biomaterials.

[6]  Gregg W Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.

[7]  Volker Klauss,et al.  Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. , 2010, The New England journal of medicine.

[8]  S. Pocock,et al.  Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.

[9]  Patrick Hunziker,et al.  Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. , 2006, Journal of the American College of Cardiology.

[10]  Renu Virmani,et al.  Pathological findings at bifurcation lesions: the impact of flow distribution on atherosclerosis and arterial healing after stent implantation. , 2010, Journal of the American College of Cardiology.

[11]  G. Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.

[12]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[13]  G. Stone,et al.  Predictors and Implications of Stent Thrombosis in Non–ST-Segment Elevation Acute Coronary Syndromes: The ACUITY Trial , 2011, Circulation. Cardiovascular interventions.

[14]  A. Colombo,et al.  Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment , 2007, Circulation.

[15]  J. Popma,et al.  The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). , 2004, Journal of the American College of Cardiology.

[16]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration , 2009, BMJ : British Medical Journal.

[17]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[18]  I Harvey,et al.  Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. , 2008, Journal of clinical epidemiology.

[19]  C. Sosnowski.  [Commentary to the article: Kedhi E, Joesoef KS, McFadden E et al. Second-generation everolimus- -eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet, 2010; 375: 201-209]. , 2010, Kardiologia polska.

[20]  E. Edelman,et al.  Stent Thrombogenicity Early in High-Risk Interventional Settings Is Driven by Stent Design and Deployment and Protected by Polymer-Drug Coatings , 2011, Circulation.

[21]  C. Terkelsen,et al.  Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention: The Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV) , 2012, Circulation.

[22]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[23]  L. Räber,et al.  Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization. , 2011, Journal of the American College of Cardiology.

[24]  A. Kastrati,et al.  Everolimus-Eluting Versus Sirolimus-Eluting StentsClinical Perspective , 2011 .

[25]  Gregg W Stone,et al.  Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. , 2010, The New England journal of medicine.

[26]  Ron Goeree,et al.  Effectiveness and safety of drug-eluting stents in Ontario. , 2007, The New England journal of medicine.

[27]  Ralph D'Agostino,et al.  Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.

[28]  P. Smits,et al.  Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial , 2010, The Lancet.

[29]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[30]  R. Virmani,et al.  Endothelial cell recovery between comparator polymer-based drug-eluting stents. , 2008, Journal of the American College of Cardiology.

[31]  Jui-Che Lin,et al.  Surface characterization and platelet adhesion studies on fluorocarbons prepared by plasma-induced graft polymerization , 2000, Journal of biomaterials science. Polymer edition.

[32]  A. Kastrati,et al.  Everolimus-Eluting Versus Sirolimus-Eluting Stents: A Meta-Analysis of Randomized Trials , 2011, Circulation. Cardiovascular interventions.

[33]  C. Vrints,et al.  Stent thrombosis with drug-eluting and bare-metal stents , 2012, The Lancet.

[34]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.